← All trials
NCT06436781
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2024
- Primary completion
- May 30, 2025
- Completion date
- Aug 31, 2025
- First posted
- May 31, 2024
- Last posted
- Oct 16, 2024
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- RDC Clinical Pty LtdLead sponsor
- RDC Clinical Pty LtdOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.